3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Skin Neoplasms
1
Radiodermatitis
1
Neoplasms, Squamous Cell
1
Melanoma
1
Immune System Diseases
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
13
fludarabine
8
fludarabine phosphate
7
Busulfan
5
Bendamustine Hydrochloride
5
Tacrolimus
4
Rituximab
4
Mycophenolic Acid
4
ibrutinib
3
Melphalan
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
ponatinib
2
pembrolizumab
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
AP 1903 reagent
2
thymoglobulin
1
palbociclib
1
ibritumomab tiuxetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Immune System Diseases
×
Dimethyl Sulfoxide
×
Clear all
NCT02519816
2019-08-14
CARE
Maisonneuve-Rosemont Hospital
Phase 2
Unknown
17 enrolled